NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Werewolf Therapeutics, Inc. (HOWL) Stock Analysis

Werewolf Therapeutics, Inc. (HOWL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HOWL

$0.97

+$0.02 (+2.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HOWL with… →

HOWL Key Statistics

As of Sep 4, 2026
Trading
Open
$0.94
Previous Close
$0.94
Day's Range
0.93–0.97
52-Week Range
0.27–2.38
Volume
487.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.51
Valuation
Market Cap
$46.96M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.74
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$60.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
−164.82%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.60M
1-Year Return
−28.44%
Dividend and dates
Earnings Date
October 30, 2026estimated
Avg Volume
7.00M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HOWL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+52.37%
2025−57.16%
2024−61.66%
2023+88.29%
2022−82.79%
2021 (partial year)−26.02%

As of September 4, 2026.

HOWL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$60.82M—
2024$1.89M−$70.52M−3740.8%
2023$19.94M−$37.37M−187.4%
2022$16.40M−$53.81M−328.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$60.68M−$60.82M—
2024$1.89M—−$73.59M−$70.52M−3740.8%
2023$19.94M—−$40.50M−$37.37M−187.4%
2022$16.40M—−$56.06M−$53.81M−328.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HOWL Valuation vs Biotechnology Median

Median of 656 stocks
MetricHOWLBiotechnology medianvs median
P/S ratio2.2415.260.1x the median
Profit margin−164.82%0.00%164.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Werewolf Therapeutics, Inc. (HOWL) is capitalised at $46.96M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 39.

The 52-week range on file runs from $0.27 to $2.38. HOWL last closed at $0.97 on September 4, 2026. That is +$0.02 (+2.33%) against the previous close. The latest close sits 257.78% above that 52-week low.

Financial Health

In fiscal 2025, Werewolf Therapeutics, Inc. reported revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $1.89M. The same year closed with a net loss of $60.82M. Profit margin runs at −164.82%. That is 164.8 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.74.

Across the 4 fiscal years on file, revenue moves from $16.40M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.24 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −28.44%. Measured over 5 years, that is −44.13% a year compounded. The reported beta is 0.51. Annualized volatility over the trailing 5 years is 113.39%.

Growth & Income

No dividend is on file for HOWL.

The strongest complete calendar year on file is 2023 at +88.29%; the weakest is 2022 at −82.79%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the price is +52.37% year to date.

Peer Comparison

Werewolf Therapeutics, Inc. (HOWL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Werewolf Therapeutics, Inc. HOWL $46.96M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Werewolf Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Visit website →